We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Ilaris Approved for Extended Use in Periodic Fever
Read MoreHide Full Article
Switzerland-based Novartis AG (NVS - Free Report) announced that its arthritis drug, Ilaris, was approved in the U.S. for expanded use in the treatment of three distinct types of periodic fever syndromes – tumor necrosis factor-receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD) and familial Mediterranean fever (FMF).
The approvals were based on positive results from a pivotal phase III study, CLUSTER, which demonstrated rapid and sustained disease control through 16-weeks in patients with TRAPS, HIDS/MKD or FMF, in comparison to placebo.
In both the U.S. and the EU, Ilaris is already approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) and systemic juvenile idiopathic arthritis (SJIA). In the EU, Ilaris is approved for the treatment of patients with adult-onset still's disease (AOSD) and the symptomatic treatment of refractory acute gouty arthritis. The drug is currently approved in more than 70 countries.
Note that Ilaris generated sales of $135 million in the first six moths of 2016, up 19% from the year-ago comparable period. The recent approval in additional indications should boost sales further.
Novartis currently carries a Zacks Rank #3 (Hold).
Corcept Therapeutics witnessed an increase of 25% and 12.5% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. The company has posted a positive earnings surprise in three out of the last four quarters, bringing the average beat to 100%. The company’s share price has surged 39.3% year to date.
Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company’s earnings have beaten estimates in each of the last four quarters with an average beat of 42.19%. The company’s share price has jumped 23.2% year to date.
Over the past 60 days, Cambrex’s earnings estimates for 2016 and 2017 have increased by 5.6% and 5.8%, respectively. The company has delivered a positive earnings surprise thrice in the trailing four quarters, with an average beat of 19.42%. Share price of the company has gained 4.9% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Novartis Ilaris Approved for Extended Use in Periodic Fever
Switzerland-based Novartis AG (NVS - Free Report) announced that its arthritis drug, Ilaris, was approved in the U.S. for expanded use in the treatment of three distinct types of periodic fever syndromes – tumor necrosis factor-receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD) and familial Mediterranean fever (FMF).
The approvals were based on positive results from a pivotal phase III study, CLUSTER, which demonstrated rapid and sustained disease control through 16-weeks in patients with TRAPS, HIDS/MKD or FMF, in comparison to placebo.
In both the U.S. and the EU, Ilaris is already approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) and systemic juvenile idiopathic arthritis (SJIA). In the EU, Ilaris is approved for the treatment of patients with adult-onset still's disease (AOSD) and the symptomatic treatment of refractory acute gouty arthritis. The drug is currently approved in more than 70 countries.
NOVARTIS AG-ADR Price
NOVARTIS AG-ADR Price | NOVARTIS AG-ADR Quote
Note that Ilaris generated sales of $135 million in the first six moths of 2016, up 19% from the year-ago comparable period. The recent approval in additional indications should boost sales further.
Novartis currently carries a Zacks Rank #3 (Hold).
Stocks to Consider
A few better-ranked stocks in the health care sector include Corcept Therapeutics Incorporated (CORT - Free Report) , Anika Therapeutics, Inc. (ANIK - Free Report) and Cambrex Corporation . All of the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Corcept Therapeutics witnessed an increase of 25% and 12.5% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. The company has posted a positive earnings surprise in three out of the last four quarters, bringing the average beat to 100%. The company’s share price has surged 39.3% year to date.
Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company’s earnings have beaten estimates in each of the last four quarters with an average beat of 42.19%. The company’s share price has jumped 23.2% year to date.
Over the past 60 days, Cambrex’s earnings estimates for 2016 and 2017 have increased by 5.6% and 5.8%, respectively. The company has delivered a positive earnings surprise thrice in the trailing four quarters, with an average beat of 19.42%. Share price of the company has gained 4.9% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>